These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

483 related items for PubMed ID: 35792049

  • 1. High clustering rate and genotypic drug-susceptibility screening for the newly recommended anti-tuberculosis drugs among global extensively drug-resistant Mycobacterium tuberculosis isolates.
    Trisakul K, Nonghanphithak D, Chaiyachat P, Kaewprasert O, Sakmongkoljit K, Reechaipichitkul W, Chaiprasert A, Blair D, Clark TG, Faksri K.
    Emerg Microbes Infect; 2022 Dec; 11(1):1857-1866. PubMed ID: 35792049
    [Abstract] [Full Text] [Related]

  • 2. In Vitro Drug Susceptibility of Bedaquiline, Delamanid, Linezolid, Clofazimine, Moxifloxacin, and Gatifloxacin against Extensively Drug-Resistant Tuberculosis in Beijing, China.
    Pang Y, Zong Z, Huo F, Jing W, Ma Y, Dong L, Li Y, Zhao L, Fu Y, Huang H.
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739779
    [Abstract] [Full Text] [Related]

  • 3. First report of whole-genome analysis of an extensively drug-resistant Mycobacterium tuberculosis clinical isolate with bedaquiline, linezolid and clofazimine resistance from Uganda.
    Kabahita JM, Kabugo J, Kakooza F, Adam I, Guido O, Byabajungu H, Namutebi J, Namaganda MM, Lutaaya P, Otim J, Kakembo FE, Kanyerezi S, Nabisubi P, Sserwadda I, Kasule GW, Nakato H, Musisi K, Oola D, Joloba ML, Mboowa G.
    Antimicrob Resist Infect Control; 2022 May 12; 11(1):68. PubMed ID: 35550202
    [Abstract] [Full Text] [Related]

  • 4. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.
    Yang JS, Kim KJ, Choi H, Lee SH.
    Ann Lab Med; 2018 Nov 12; 38(6):563-568. PubMed ID: 30027700
    [Abstract] [Full Text] [Related]

  • 5. Whole-genome sequencing of clinical isolates from tuberculosis patients in India: real-world data indicates a high proportion of pre-XDR cases.
    Bhanushali A, Atre S, Nair P, Thandaseery GA, Shah S, Kuruwa S, Zade A, Nikam C, Gomare M, Chatterjee A.
    Microbiol Spectr; 2024 May 02; 12(5):e0277023. PubMed ID: 38597637
    [Abstract] [Full Text] [Related]

  • 6. A Narrative Review of Bedaquiline and Delamanid: New Arsenals Against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis.
    Ahmad Khosravi N, Sirous M, Khosravi AD, Saki M.
    J Clin Lab Anal; 2024 Aug 02; 38(15-16):e25091. PubMed ID: 39431709
    [Abstract] [Full Text] [Related]

  • 7. Prevalence of Mycobacterium tuberculosis resistant to bedaquiline and delamanid in China.
    He W, Liu C, Liu D, Ma A, Song Y, He P, Bao J, Li Y, Zhao B, Fan J, Cheng Q, Zhao Y.
    J Glob Antimicrob Resist; 2021 Sep 02; 26():241-248. PubMed ID: 34214699
    [Abstract] [Full Text] [Related]

  • 8. Investigation of genomic mutations and their association with phenotypic resistance to new and repurposed drugs in Mycobacterium tuberculosis complex clinical isolates.
    Mok S, Roycroft E, Flanagan PR, Wagener J, Fitzgibbon MM.
    J Antimicrob Chemother; 2023 Nov 06; 78(11):2637-2644. PubMed ID: 37740935
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region.
    Dreyer V, Mandal A, Dev P, Merker M, Barilar I, Utpatel C, Nilgiriwala K, Rodrigues C, Crook DW, CRyPTIC Consortium, Rasigade JP, Wirth T, Mistry N, Niemann S.
    Genome Med; 2022 Aug 22; 14(1):95. PubMed ID: 35989319
    [Abstract] [Full Text] [Related]

  • 13. Prevalence and molecular characterizations of seven additional drug resistance among multidrug-resistant tuberculosis in China: A subsequent study of a national survey.
    Wang G, Jiang G, Jing W, Zong Z, Yu X, Chen S, Li W, Huang H.
    J Infect; 2021 Mar 22; 82(3):371-377. PubMed ID: 33556430
    [Abstract] [Full Text] [Related]

  • 14. Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China.
    Zheng H, He W, Jiao W, Xia H, Sun L, Wang S, Xiao J, Ou X, Zhao Y, Shen A.
    BMC Infect Dis; 2021 Apr 08; 21(1):330. PubMed ID: 33832459
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis.
    Wen S, Jing W, Zhang T, Zong Z, Xue Y, Shang Y, Wang F, Huang H, Chu N, Pang Y.
    Eur J Clin Microbiol Infect Dis; 2019 Jul 08; 38(7):1293-1296. PubMed ID: 30953211
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Epidemiology of extensively drug-resistant tuberculosis among patients with multidrug-resistant tuberculosis: A systematic review and meta-analysis.
    Diriba G, Alemu A, Yenew B, Tola HH, Gamtesa DF, Mollalign H, Eshetu K, Moga S, Abdella S, Tollera G, Kebede A, Dangisso MH.
    Int J Infect Dis; 2023 Jul 08; 132():50-63. PubMed ID: 37072053
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.